CORRECTING and REPLACING Actinium Pharmaceuticals, Inc. Launches Development of Antibody Actinium-225 Labeling Construct To Support Third Clinical Program

Development Of Actinium 225 Labeled Antibody Targeted at Selected Hematologic Malignancies

NEW YORK--


The corrected release reads:

ACTINIUM PHARMACEUTICALS, INC. LAUNCHES DEVELOPMENT OF ANTIBODY ACTINIUM-225 LABELING CONSTRUCT TO SUPPORT THIRD CLINICAL PROGRAM

Development Of Actinium 225 Labeled Antibody Targeted at Selected Hematologic Malignancies

Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) (“Actinium” or “the Company”), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers initiated development of an additional antibody construct labeled with actinium-225. The antibody has the potential to be used in treatment of a number of blood cancers. Preclinical work for this additional antibody will be done at Memorial Sloan Kettering Cancer Center. A significant amount of both clinical and preclinical data for the antibody labeled with other payloads is available from numerous clinical trials in a number of indications. Assuming success of this program, Actinium will select the appropriate indication for clinical development of the new construct.

“We continue to work with leading institutions including Memorial Sloan Kettering to leverage the broad utility of our alpha particle immunotherapy platform, a highly potent and selective form of targeted radiotherapy, to address significant unmet patient need in
various cancer types”, commented Dr. Kaushik J. Dave, President and CEO of Actinium Pharmaceuticals. “Clinical trials of drug candidates based on alpha emitting isotopes have demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery. If successful, we believe this approach will further expand the field of use of alpha emitters.”

Arming a versatile antibody with actinium-225 will allow further customization of treatment in various blood cancer indications and its use in expanded clinical settings due to very low levels of radiation exposure to medical personnel, other caregivers and environment. Pending successful results of the preclinical work, development will continue in clinical trials.

Alpha emitters deposit higher energy over a much shorter distance compared with beta emitters, providing single-cell kill while sparing normal surrounding tissue. Increased cell-specific potency may provide less off-target toxicity, resulting in an approach that decreases relapse rates and is better tolerated by patients. Alpha emitters may prove particularly useful for minimal-residual disease or extramedullary disease (located outside of the bone marrow), as well as in the non- hematopoietic stem cell transplantation (HSCT) setting, if conjugated/connected to select target antigens.

About Actinium 225

Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alphaparticle, increasing the chances that the cancer cell will be destroyed. The technology was first demonstrated at Memorial Sloan Kettering Cancer Center.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (www.actiniumpharma.com) is a New York-based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha-emitting actinium-225 and bismuth-213 and certain beta emitting radiopharmaceuticals in conjunction with monoclonal antibodies. The Company’s lead radiopharmaceutical Iomab™-B will be used in preparing patients for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The Company is preparing a single, pivotal, multicenter Phase 3 clinical study of Iomab™-B in refractory and relapsed Acute Myeloid Leukemia (AML) patients over the age of 55 with a primary endpoint of durable complete remission. The Company’s second program, Actimab-A, is continuing its clinical development in a Phase 1/2 trial for newly diagnosed AML patients over the age of 60 in a single-arm multicenter trial.

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements
may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Actinium Pharmaceuticals, Inc.  
Evan Smith, CFA, +1 646-840-5442,  
VP Investor Relations and Finance  
esmith@actiniumpharma.com

Source: Actinium Pharmaceuticals, Inc.